Literature DB >> 21212285

Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.

Luciana Teofili1, Maurizio Martini, Maria Grazia Iachininoto, Sara Capodimonti, Eugenia Rosa Nuzzolo, Lorenza Torti, Tonia Cenci, Luigi Maria Larocca, Giuseppe Leone.   

Abstract

In this study we investigated whether neoplastic transformation occurring in Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs) could involve also the endothelial cell compartment. We evaluated the level of endothelial colony-forming cells (E-CFCs) in 42 patients (15 with polycythemia vera, 12 with essential thrombocythemia, and 15 with primary myelofibrosis). All patients had 1 molecular abnormality (JAK2(V617F) or MPL(W515K) mutations, SOCS gene hypermethylation, clonal pattern of growth) detectable in their granulocytes. The growth of colonies was obtained in 22 patients and, among them, patients with primary myelofibrosis exhibited the highest level of E-CFCs. We found that E-CFCs exhibited no molecular abnormalities in12 patients, had SOCS gene hypermethylation, were polyclonal at human androgen receptor analysis in 5 patients, and resulted in JAK2(V617F) mutated and clonal in 5 additional patients, all experiencing thrombotic complications. On the whole, patients with altered E-CFCs required antiproliferative therapy more frequently than patients with normal E-CFCs. Moreover JAK2(V617F)-positive E-CFCs showed signal transducer and activator of transcription 5 and 3 phosphorylation rates higher than E-CFCs isolated from healthy persons and patients with MPN without molecular abnormalities. Finally, JAK2(V617F)-positive E-CFCs exhibited a high proficiency to adhere to normal mononuclear cells. This study highlights a novel mechanism underlying the thrombophilia observed in MPN.
© 2011 by The American Society of Hematology

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212285     DOI: 10.1182/blood-2010-07-297598

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  CD133 marks a stem cell population that drives human primary myelofibrosis.

Authors:  Ioanna Triviai; Thomas Stübig; Birte Niebuhr; Kais Hussein; Asterios Tsiftsoglou; Boris Fehse; Carol Stocking; Nicolaus Kröger
Journal:  Haematologica       Date:  2015-02-27       Impact factor: 9.941

2.  Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential.

Authors:  Eugenia R Nuzzolo; Sara Capodimonti; Maurizio Martini; Maria G Iachininoto; Maria Bianchi; Alessandra Cocomazzi; Gina Zini; Giuseppe Leone; Luigi M Larocca; Luciana Teofili
Journal:  Blood Transfus       Date:  2013-06-19       Impact factor: 3.443

Review 3.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 4.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

Review 5.  The marrow stem cell niche in normal and malignant hematopoiesis.

Authors:  Kenneth Kaushansky; Huichun Zhan
Journal:  Ann N Y Acad Sci       Date:  2019-02-14       Impact factor: 5.691

6.  Myeloproliferative Neoplasms, an Acquired Thrombophilic State: JAK2 and Beyond.

Authors:  Hara Prasad Pati; Prashant Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-17       Impact factor: 0.900

Review 7.  Endothelial progenitor cells in hematologic malignancies.

Authors:  Ugo Testa; Ernestina Saulle; Germana Castelli; Elvira Pelosi
Journal:  Stem Cell Investig       Date:  2016-07-01

Review 8.  Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.

Authors:  Joan How; Amy Zhou; Stephen T Oh
Journal:  Ther Adv Hematol       Date:  2016-12-08

Review 9.  Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.

Authors:  Alexandre Guy; Johanne Poisson; Chloe James
Journal:  Leukemia       Date:  2021-03-03       Impact factor: 11.528

10.  JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.

Authors:  S Leah Etheridge; Michelle E Roh; Megan E Cosgrove; Veena Sangkhae; Norma E Fox; Junmei Chen; José A López; Kenneth Kaushansky; Ian S Hitchcock
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.